SCHEMBL14760574

SCHEMBL14760574

CNC(=O)C=Cc1cccc(Nc2nccc(Nc3ccc4[nH]c(C)cc4c3F)n2)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 2/20 0.45
MAPK8 P45983 3/20 0.41
PIM1 P11309 2/20 0.41
CDK2 P24941 2/20 0.41
GSK3B P49841 2/20 0.41
HIPK2 Q9H2X6 2/20 0.41
CLK4 Q9HAZ1 2/20 0.41
AURKA O14965 2/20 0.41
AURKB Q96GD4 2/20 0.41
DAPK3 O43293 1/20 0.41
JAK2 O60674 1/20 0.41
PRKD3 O94806 1/20 0.41
PRKACA P17612 1/20 0.41
FLT3 P36888 1/20 0.41
CSNK1A1 P48729 1/20 0.41
CDK8 P49336 1/20 0.41
CLK2 P49760 1/20 0.41
GSK3A P49840 1/20 0.41
CDK9 P50750 1/20 0.41
RPS6KA3 P51812 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14024645 1.00 KDR (0.45) KDRMAPK8PIM1CDK2GSK3B
SCHEMBL14024613 0.85 BTK (0.41) KDRMAPK8PIM1CDK2GSK3B
SCHEMBL14760719 0.85 BTK (0.41) KDRMAPK8PIM1CDK2GSK3B
SCHEMBL14760730 0.85 MAOB (0.53) KDRITKHDAC3HDAC4HDAC1
SCHEMBL14024428 0.85 MAOB (0.53) KDRITKHDAC3HDAC4HDAC1
SCHEMBL4875599 0.84 KDR (0.65) KDRFLT3HDAC3HDAC4HDAC1
SCHEMBL4875588 0.84 KDR (0.65) KDRFLT3HDAC3HDAC4HDAC1
SCHEMBL14024607 0.84 NPC1 (0.48) KDRAURKAEPHB4PKMYT1LYN
SCHEMBL14024755 0.82 SYK (0.58) KDRMAPK8PIM1CDK2GSK3B
SCHEMBL4879994 0.82 CDK2 (0.53) KDRMAPK8PIM1CDK2GSK3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2154967-B9 PYRIMIDINE DERIVATIVES HUTCHISON MEDIPHARMA ENTPR LTD (BS) 2014-07-23 EP claimed
EP-2154967-B1 PYRIMIDINE DERIVATIVES HUTCHISON MEDIPHARMA ENTPR LTD (BS) 2014-03-05 EP claimed
US-8901143-B2 Pyrimidine derivatives HUTCHISON MEDIPHARMA ENTERPRISES LIMITED (BS) 2014-12-02 US disclosed
EP-2154967-B9 PYRIMIDINE DERIVATIVES HUTCHISON MEDIPHARMA ENTPR LTD (BS) 2014-07-23 EP disclosed
EP-2154967-B1 PYRIMIDINE DERIVATIVES HUTCHISON MEDIPHARMA ENTPR LTD (BS) 2014-03-05 EP disclosed
US-20130065890-A1 PYRIMIDINE DERIVATIVES HUTCHISON MEDIPHARMA ENTERPRISES LIMITED 2013-03-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130065890-A1 PYRIMIDINE DERIVATIVES TYMS, KDR, FLT4 KDR 2/4885MAPK8 3700/4885PIM1 3454/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.